RPR acquring U.S. rights to the bone metabolism therapy, which it will develop in both new I.V. and oral forms. Rhone-Poulenc Rorer already markets the Astra product in France and will be launched in other European countries in the near-term. RPR concurrently is selling to Astra for cash five non-strategic hospital products: MVI, Aquasol A and E, Arm-a-Med and Arm-a-Vial. Deal is second non-strategic asset divestiture announced by RPR in
You may also be interested in...
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.